More information: Kai Chen et al, mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer, Cancer Research (2024). DOI: 10.1158/0008-5472.CAN-24-0984 ...

Ohio State has submitted a provisional patent application for the technologies. Reference: Chen K, Ernst P, Sarkar A, et al. mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer.

Gene editing technologies have revolutionized the field of genetics, allowing researchers to make targeted changes to the DNA of various animal and plant nuclei, animal mitochondria, plant ...

The results suggest that using this gene expression control system likely has broad confounding ... “This is a straightforward and clear story,” said Cole Haynes, who studies mitochondrial dysfunction ...

the company’s investigational gene therapy for Leber Hereditary Optic Neuropathy (LHON) due to a mutated ND4 mitochondrial gene. The patients had all participated in the phase III trials RESCUE and ...

Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...

"We also observed defects in metabolism and mitochondria structure and performance ... They found that this gene therapy approach significantly boosted hemoglobin and red blood cell levels ...

is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based ...